Carsten Browall proposed as new Chairman of Vitrolife AB

The Election Committee of Vitrolife AB (publ) has proposed Carsten Browall as
the new Chairman of the Board. Carsten Browall is today a member of the
company’s Board and he has many years of experience in medical device and the
healthcare sector.
Vitrolife’s Election Committee today announced that it proposes that the Annual
General Meeting elect Carsten Browall as the company’s new Chairman of the
Board. Carsten Browall has been a member of the Vitrolife Board since 2012 and
has many years of experience from executive positions within medical device and
the healthcare sector, amongst other things from Unfors RaySafe, Mölnlycke
Health Care, Nobel Biocare and Capio.

“It is an honour to be asked to take over the position of Chairman and it will
be immensely exciting to continue the work on Vitrolife’s successful journey
together with the Board and the executive management,” says Carsten Browall.

The present Chairman of the Board, Patrik Tigerschiöld, has declined reelection
after 13 years on the Board and 11 years as its Chairman.

“It has been a very successful period for Vitrolife and it now feels natural to
hand over the Chairman’s gavel to Carsten Browall, who I am convinced is the
right person to lead the Board in the company’s next phase. I would like to make
clear that my decision to leave the Board shall in no way be seen as Bure
Equity, which is the largest owner, having a changed view of its shareholding in
Vitrolife,” says Patrik Tigerschiöld.

Gothenburg, March 25, 2013

VITROLIFE AB (publ)
Queries should be addressed to:

Patrik Tigerschiöld, Chairman of the Board, phone 46 8 614 00 20
Carsten Browall, Board member, phone + 46 70 255 65 32

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on March
25, at 5.00 p.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife (http://www.vitrolife.com/en/Corporate/) is a global medical device
Group. Vitrolife Fertility (http://www.vitrolife.com/en/Fertility/) product area
develops, produces and markets products for the treatment of human infertility.
Work is also carried out to enable the use and handling of stem cells for
therapeutic purposes

Vitrolife (http://www.vitrolife.com/en/Corporate/) has approximately 230
employees and the company's products are sold in about 100 markets. The company
is headquartered in Gothenburg, Sweden, and there are also offices in USA,
Australia, France, Italy, United Kingdom, China, Japan and Hungary. The
Vitrolife share (http://www.vitrolife.com/en/Corporate/Financial/The-share1/) is
listed on NASDAQ OMX
Stockholm (http://www.nasdaqomxnordic.com/aktier/shareinformation?Instrument=SSE
1 
3469), Small Cap.

________________________________________________________________________________
_ 
________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/
Carsten Browall proposed as new Chairman of Vitrolife AB (publ)

Attachments
